Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

@article{PanditTaskar2018BiodistributionAD,
  title={Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.},
  author={Neeta Pandit-Taskar and Pat Zanzonico and Kevin D Staton and Jorge A. Carrasquillo and Diane L. Reidy-Lagunes and Serge K. Lyashchenko and Eva M Burnazi and Hanwen Zhang and Jason S Lewis and Ronald G. Blasberg and Steven M. Larson and Wolfgang Weber and Shakeel Modak},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2018},
  volume={59 1},
  pages={
          147-153
        }
}
123I-meta-iodobenzylguanidine (123I-MIBG) imaging is currently a mainstay in the evaluation of many neuroendocrine tumors, especially neuroblastoma. 123I-MIBG imaging has several limitations that can be overcome by the use of a PET agent. 18F-meta-fluorobenzylguanidine (18F-MFBG) is a PET analog of MIBG that may allow for single-day, high-resolution quantitative imaging. We conducted a first-in-human study of 18F-MFBG PET imaging to evaluate the safety, feasibility, pharmacokinetics, and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Concentration of 123Imetaiodobenzylguanidine in left and right liver lobes. Findings indicate by NYU Med Ctr Lib - Periodicals

  • H Jacobsson, L Johansson, S Kimiaei, SA. Larsson
  • Dept on July 15,
  • 2017

Similar Papers

Loading similar papers…